PCSK6 and Survival in Idiopathic Pulmonary Fibrosis (2023)
Journal Article
Oldham, J. M., Allen, R. J., Lorenzo-Salazar, J. M., Molyneaux, P. L., Ma, S., Joseph, C., …Noth, I. (2023). PCSK6 and Survival in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, https://doi.org/10.1164/rccm.202205-0845OC

Investigating the diagnostic utility of high-resolution oesophageal manometry in patients with refractory respiratory symptoms (2022)
Journal Article
Sykes, D. L., Crooks, M. G., Hart, S. P., Jackson, W., Gallagher, J., & Morice, A. H. (2022). Investigating the diagnostic utility of high-resolution oesophageal manometry in patients with refractory respiratory symptoms. Respiratory medicine, 202, Article 106985. https://doi.org/10.1016/j.rmed.2022.106985

Background: The interaction between the respiratory and gastrointestinal systems, and the role of the latter in the development of respiratory pathology, has been examined with a focus on gastro-oesophageal reflux disease (GORD). However, little data... Read More about Investigating the diagnostic utility of high-resolution oesophageal manometry in patients with refractory respiratory symptoms.

Mixed-methods feasibility cluster randomised controlled trial of a paramedic-administered breathlessness management intervention for acute-on-chronic breathlessness (BREATHE): study findings (2022)
Journal Article
Hutchinson, A., Allgar, V., Cohen, J., Currow, D. C., Griffin, S., Hart, S., …Johnson, M. J. (2022). Mixed-methods feasibility cluster randomised controlled trial of a paramedic-administered breathlessness management intervention for acute-on-chronic breathlessness (BREATHE): study findings. ERJ Open Research, 8(4), Article 00257-2022. https://doi.org/10.1183/23120541.00257-2022

Introduction: One-fifth of emergency department presentations by ambulance are due to acute-on-chronic breathlessness. We explored the feasibility of an evaluation-phase, cluster randomised controlled trial (cRCT) of the effectiveness and cost-effect... Read More about Mixed-methods feasibility cluster randomised controlled trial of a paramedic-administered breathlessness management intervention for acute-on-chronic breathlessness (BREATHE): study findings.

Genome-wide association study across five cohorts identifies five novel loci associated with idiopathic pulmonary fibrosis (2022)
Journal Article
Allen, R. J., Stockwell, A., Oldham, J. M., Guillen-Guio, B., Schwartz, D. A., Maher, T. M., …Wain, L. V. (2022). Genome-wide association study across five cohorts identifies five novel loci associated with idiopathic pulmonary fibrosis. Thorax, 77, 829-833. https://doi.org/10.1136/thoraxjnl-2021-218577

Idiopathic pulmonary fibrosis (IPF) is a chronic lung condition with poor survival times. We previously published a genome-wide meta-analysis of IPF risk across three studies with independent replication of associated variants in two additional studi... Read More about Genome-wide association study across five cohorts identifies five novel loci associated with idiopathic pulmonary fibrosis.

Bruton’s tyrosine kinase inhibitors impair FcγRIIA-driven platelet responses to bacteria in chronic lymphocytic leukemia (2021)
Journal Article
Naylor-Adamson, L., Chacko, A., Booth, Z., Caserta, S., Jarvis, J., Khan, S., …Arman, M. (2021). Bruton’s tyrosine kinase inhibitors impair FcγRIIA-driven platelet responses to bacteria in chronic lymphocytic leukemia. Frontiers in immunology, 12, Article 766272. https://doi.org/10.3389/fimmu.2021.766272

Bacterial infections are a major cause of morbidity and mortality in chronic lymphocytic leukemia (CLL), and infection risk increases in patients treated with the Bruton’s tyrosine kinase (Btk) inhibitor, ibrutinib. Btk and related kinases (like Tec)... Read More about Bruton’s tyrosine kinase inhibitors impair FcγRIIA-driven platelet responses to bacteria in chronic lymphocytic leukemia.

A feasibility cluster randomised controlled trial of a paramedic-administered breathlessness management intervention for acute-on-chronic breathlessness (BREATHE): Study protocol (2021)
Journal Article
Northgraves, M., Cohen, J., Allgar, V., Currow, D., Hart, S., Hird, K., …Hutchinson, A. (2021). A feasibility cluster randomised controlled trial of a paramedic-administered breathlessness management intervention for acute-on-chronic breathlessness (BREATHE): Study protocol. ERJ Open Research, 7(1), Article 00955-2020. https://doi.org/10.1183/23120541.00955-2020

Introduction: Chronic breathlessness, persistent and disabling despite optimal treatment of underlying causes, is a prevalent and frightening symptom and is associated with many emergency presentations and admission to hospital. Breathlessness manage... Read More about A feasibility cluster randomised controlled trial of a paramedic-administered breathlessness management intervention for acute-on-chronic breathlessness (BREATHE): Study protocol.

Distinct immune regulatory receptor profiles linked to altered monocyte subsets in sarcoidosis (2020)
Journal Article
Fraser, S. D., Crooks, M. G., Kaye, P. M., & Hart, S. P. (2021). Distinct immune regulatory receptor profiles linked to altered monocyte subsets in sarcoidosis. ERJ Open Research, 7(1), https://doi.org/10.1183/23120541.00804-2020

Background: In sarcoidosis, blood monocytes, circulating precursors of granuloma macrophages, display enhanced inflammatory cytokine production, reduced expression of the regulatory (inhibitory) receptor CD200R, and altered subsets defined by CD14 an... Read More about Distinct immune regulatory receptor profiles linked to altered monocyte subsets in sarcoidosis.

BTS Clinical Statement on pulmonary sarcoidosis (2020)
Journal Article
Thillai, M., Atkins, C. P., Crawshaw, A., Hart, S. P., Ho, L. P., Kouranos, V., …Wells, A. U. (in press). BTS Clinical Statement on pulmonary sarcoidosis. Thorax, https://doi.org/10.1136/thoraxjnl-2019-214348

Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease: An International Multicenter Study (2020)
Journal Article
Drake, T. M., Docherty, A. B., Harrison, E. M., Quint, J. K., Adamali, H., Agnew, S., …ISARIC4C Investigators. (2020). Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease: An International Multicenter Study. American Journal of Respiratory and Critical Care Medicine, 202(12), 1656-1665. https://doi.org/10.1164/rccm.202007-2794OC

Rationale: The impact of coronavirus disease (COVID-19) on patients with interstitial lung disease (ILD) has not been established.Objectives: To assess outcomes in patients with ILD hospitalized for COVID-19 versus those without ILD in a contemporane... Read More about Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease: An International Multicenter Study.

Azithromycin for sarcoidosis cough: an open label exploratory clinical trial (2020)
Journal Article
Fraser, S. D., Thackray-Nocera, S., Shepherd, M., Flockton, R., Wright, C., Sheedy, W., …Hart, S. P. (2020). Azithromycin for sarcoidosis cough: an open label exploratory clinical trial. ERJ Open Research, 6(4), Article 00534. https://doi.org/10.1183/23120541.00534-2020

Background: Chronic cough is a distressing symptom for many people with pulmonary sarcoidosis. Continuous treatment with a macrolide antibiotic may improve cough. We aimed to assess the potential efficacy of azithromycin in patients with sarcoidosis... Read More about Azithromycin for sarcoidosis cough: an open label exploratory clinical trial.